The company said the layoffs and cost reductions are part of a restructuring plan that will adjust and optimize its supply chain network.
“We do expect some employee attrition and limited headcount reductions to result from these restructuring activities. We are committed to providing these individuals our support to help with their transition,” Boston Scientific stated.
The company said that while job cuts will take place, its headcount will remain relatively stable because it plans to create jobs in growth areas.
The restructuring is expected to be complete by the end of 2021.
More articles on supply chain:
Samsung Galaxy wants to help patients manage insulin therapy
Red Cross issues call for blood donations ahead of holidays
FDA’s cybersecurity policies for postmarket medical devices are ‘insufficient,’ OIG finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
